Find policies, billing codes, payers, states, and providers
Intravenous Anesthetics for the Treatment of Chronic Pain and Psychiatric or Substance Use Disorders
Customize your policy alerts
Sign up for Premera Bluecross Policy 5.01.586 alerts
Get alerted when Policy 5.01.586 changes without checking for updates manually.
Monitor payer policy activity
Defines coverage position for intravenous infusion of anesthetics (e.g., ketamine, lidocaine) when used to treat chronic pain syndromes (including neuropathic pain, chronic daily headache, fibromyalgia) and psychiatric disorders (including depression, anxiety, OCD, PTSD, and substance use disorders). Also lists applicable CPT/HCPCS codes and summarizes evidence and guidance.
Policy updated with literature review through October 1, 2025; policy statements unchanged.
Initial policy replaced prior policy 5.01.16 and expanded to include IV ketamine for psychiatric symptoms and disorders in earlier history.
Coverage Summary
Overview: Policy 5.01.586 defines the coverage position for intravenous anesthetics (e.g., ketamine, lidocaine) when used to treat chronic pain syndromes (including neuropathic pain, chronic daily headache, fibromyalgia) and psychiatric disorders (including depression, anxiety, OCD, PTSD, and substance use disorders). Status: CURRENT; Last review: 2026-05-01 (annual review approved April 27, 2026). Scope: applies to inpatient and outpatient IV infusion protocols (subanesthetic dosing, bolus followed by infusion) investigated for these indications. Key coverage position: IV anesthetics (ketamine, lidocaine) for chronic pain and for psychiatric or substance use disorders are considered investigational and are not covered for these indications.
Medical Necessity / Investigational Determinations
Investigational / Not Medically Necessary
Intravenous infusion of anesthetics is considered investigational (unproven) for the following uses:
ALL of the following
- Intravenous infusion of anesthetics (e.g., ketamine or lidocaine) for the treatment of chronic pain, including but not limited to chronic neuropathic pain, chronic daily headache, and fibromyalgia.
- Intravenous infusion of ketamine for the treatment of depression, anxiety, or other psychiatric symptoms or disorders, including substance use disorders.
- Intravenous infusion of ketamine in conjunction with psychotherapy (ketamine-assisted therapy) for the treatment of depression, anxiety, or other psychiatric symptoms or disorders, including substance use disorders.
Evidence synthesis: For chronic pain, randomized trials and reviews have not shown durable benefit (insufficient evidence); small ketamine trials suggest only limited, short-term relief. For treatment-resistant depression, trials show short-term improvement in some studies but limited durability and concerns about controls/blinding. For other psychiatric disorders (OCD, PTSD and similar), results are mixed and overall evidence is insufficient to demonstrate net health outcome improvement.
Coding
| 0820T | Continuous in-person monitoring and intervention (e.g., psychotherapy, crisis intervention), as needed, during psychedelic medication therapy; first physician or other qualified health care professional, each hour. |
| 0821T | Continuous in-person monitoring and intervention ... second physician or other qualified health care professional, concurrent with first ... each hour (List separately in addition to code for primary procedure). |
| 0822T | Continuous in-person monitoring and intervention ... clinical staff under the direction of a physician or other qualified health care professional, concurrent ... each hour. |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour. |
| 96366 | Each additional hour (list separately in addition to code for primary procedure). |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance/drug. |
| J3490 | Unclassified drugs. |
| J2001 | Removed from policy; termed October 1, 2024. |
Provider Actions & Billing Impact
Do not cover investigational uses
Claims for IV infusion of anesthetics (for example, ketamine or lidocaine) when submitted for chronic pain (including chronic neuropathic pain, chronic daily headache, fibromyalgia) or for psychiatric or substance use disorders (including depression, anxiety, OCD, PTSD, and substance use disorders) are considered investigational and are not covered. Providers should document the indication on claims but should expect denials when these services are billed for these indications.
Provider guidance: If providers submit claims for IV ketamine or lidocaine for these investigational indications, they should document the specific indication in the claim; however, these uses are considered investigational and are not covered, and denials should be expected. The CPT and HCPCS codes listed in the policy (e.g., 0820T–0822T, 96365, 96366, 96374, J3490) may be used on claims but are not covered when billed for these investigational indications.
Background & Evidence Summary
Background: Intravenous lidocaine and ketamine have been investigated off-label for migraine and chronic daily headache, fibromyalgia, chronic neuropathic pain (including phantom limb pain, post-herpetic neuralgia, CRPS, diabetic neuropathy), and for treatment-resistant psychiatric disorders such as major depression and OCD. Typical protocols involve a series of IV infusions (subanesthetic doses with possible bolus) over days. Safety and durability concerns have been raised: adverse events can be serious (arrhythmias, seizures, dissociation, hallucinations, respiratory depression) and clinical trials have generally shown limited treatment durability.
Definitions / Glossary: • Chronic daily headache: headache occurring ≥15 days/month for ≥3 months (includes chronic migraine, new daily persistent headache, hemicrania continua, chronic tension-type headache). • Neuropathic pain: pain disproportionate to the triggering injury that may include allodynia, dysesthesia, or hyperalgesia and may persist ≥6 months after illness or injury. • Treatment-resistant depression: depression that does not respond adequately to appropriate courses of antidepressant medications.
Medicare Determinations
| Determination | Details |
|---|---|
| No national coverage determination | type: NCD; number: ; effective: |
Revision History
Annual review approved April 27, 2026. Policy updated with literature review through October 1, 2025; policy statements unchanged. Removed HCPCS code J2001 from policy (J2001 termed October 1, 2024).
Initial policy approved July 10, 2018 and posted 08/01/18; this policy replaced prior policy 5.01.16 and the coverage criteria were amended to include IV ketamine for psychiatric symptoms and disorders.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.